Chronic Inflammatory Demyelinating Polyneuropathy Market to Register Positive Growth During the Study Period (2019-2032), Evaluates DelveInsight | Key Companies to Watch Out - Octapharma, argenx, Immunovant Sciences, Sanofi, Janssen, Takeda

The chronic inflammatory demyelinating polyneuropathy market landscape continues to evolve, and several companies are furiously working toward the development of new treatments that could potentially cure and change the treatment landscape of CIDP. Companies are focused on the development of FcRN targeting therapies for the treatment of CIDP, this shall create a positive impact on the CIDP market size of the disease in coming years.

LAS VEGAS, Dec. 12, 2023 /PRNewswire/ -- DelveInsight's Chronic Inflammatory Demyelinating Polyneuropathy Market Insights report includes a comprehensive understanding of current treatment practices, chronic inflammatory demyelinating polyneuropathy emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Takeaways from the Chronic Inflammatory Demyelinating Polyneuropathy Market Report

• As per DelveInsight analysis, the total chronic inflammatory demyelinating polyneuropathy therapeutics market size in the 7MM is projected to increase during the forecast period (2023–2032).
• As per DelveInsight estimates, CIDP in the US showed that males account for the highest number of cases as compared to females in 2022.
• Globally, leading chronic inflammatory demyelinating polyneuropathy companies such as Octapharma, argenx, Immunovant Sciences GmbH, Sanofi, Janssen Research & Development, LLC, Takeda, Miltenyi Biomedicine GmbH, Nanjing IASO Biotechnology Co., Ltd., and others are developing novel CIDP drugs that can be available in the CIDP market in the coming years.
• The promising chronic inflammatory demyelinating polyneuropathy therapies in the pipeline include Panzyga, Efgartigimod, Batoclimab, SAR445088, Nipocalimab, and others.

Discover which therapies are expected to grab the major CIDP market share @ Chronic Inflammatory Demyelinating Polyneuropathy Market Report

Chronic Inflammatory Demyelinating Polyneuropathy Overview

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder that causes progressive weakness and reduced sensation in the arms and legs. It's typically due to damage to the protective covering of peripheral nerves, often triggered by the body's immune system attacking its own nerve coverings. CIDP shows itself through symmetrical weakness in the hands, feet, hips, and shoulders, gradually worsening over a minimum of two months. Other CIDP symptoms include fatigue, burning sensations, clumsiness, difficulty swallowing, and double vision. The affected muscles might appear weakened and smaller during a neurological examination due to atrophy.

Diagnosing CIDP can be challenging. Key indicators include symmetric weakness in both proximal and distal muscles, along with diminished or absent tendon reflexes, persisting for at least two months. Diagnostic tests such as a lumbar puncture, nerve conduction studies, electromyography, and MRI scans can reveal high spinal fluid protein levels, slow nerve conduction, and nerve root inflammation.

Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology Segmentation

As per DelveInsight's analysis, the age-specific data revealed that the CIDP affects more number of people after the age group of 51-60 years. As per the estimates, among the CIDP patients, the typical CIDP accounts for a higher number of CIDP cases than atypical CIDP in the United States in 2022.

The CIDP market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalent Pool of CIDP 
• Gender-specific Prevalent Pool of CIDP 
• Clinical Subtype-based (Typical/Atypical) Diagnosed Prevalent Pool of CIDP 
• Age-specific Prevalent Pool of CIDP

Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market 

The primary goal of CIDP treatment is to suppress the immune system to reduce inflammation and prevent further damage to the myelin sheath that covers nerve fibers. Intravenous immunoglobulin (IVIG) therapy is a commonly prescribed treatment for CIDP. This involves infusions of antibodies obtained from donated blood, which help modulate the immune response and alleviate symptoms. Corticosteroids, such as prednisone, may also be used to reduce inflammation. However, long-term use of corticosteroids is often avoided due to potential side effects.

For individuals who do not respond adequately to these treatments, immunosuppressive drugs like azathioprine, mycophenolate mofetil, or rituximab may be considered. Physical therapy is often recommended to maintain muscle strength and function, while pain management medications may be prescribed to address neuropathic pain associated with CIDP. The effectiveness of treatments can vary among individuals, and finding the right combination often involves a trial-and-error process. Regular monitoring and adjustments to the treatment plan may be necessary to manage CIDP effectively. Individuals with CIDP must work closely with their healthcare team to tailor a treatment strategy that addresses their specific needs and optimizes their overall well-being.

To know more about CIDP treatment guidelines, visit @ CIDP Management 

Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Therapies and Key Companies

• Panzyga: Octapharma
• Efgartigimod: argenx
• Batoclimab: Immunovant Sciences GmbH
• SAR445088: Sanofi
• Nipocalimab: Janssen Research & Development, LLC

Learn more about the FDA-approved drugs for CIDP @ Drugs for CIDP Treatment 

Chronic Inflammatory Demyelinating Polyneuropathy Market Dynamics

The dynamics of the chronic inflammatory demyelinating polyneuropathy are expected to change in the coming years. The dramatic increase in the prevalence of autoimmune diseases has paved the way for significant growth in the CIDP market. This rise in prevalence has fueled the demand for effective research and development of treatments against the disease, prompting numerous key players to actively contribute their investments. Both public and private organizations have launched initiatives and provided funding for R&D activities, resulting in positive outcomes in the field of CIDP. Recent years have witnessed a surge in novel targets, offering potential therapeutic alternatives to traditional treatments, and the introduction of various new drugs has further accelerated market growth. Additionally, active research on immunoglobulin for autoimmune diseases is expected to contribute to the expansion of the CIDP market. The development of Fc receptor antagonists holds promise as effective candidates for treating CIDP.

Furthermore, many potential therapies are being investigated for the treatment of CIDP, and it is safe to predict that the treatment space will significantly impact the CIDP market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the CIDP market in the 7MM.

However several factors may impede the growth of the CIDP market. Despite tremendous progress in elucidating disease pathogenesis, the exact triggering event remains unknown. Available treatment options, such as Hizentra and Privigen, have tolerability issues for some patients, and the high cost of these therapies is a significant challenge. Additionally, multiple immunoglobulins are in off-label use, hindering the CIDP market growth of various approved therapies. While Fc receptor antagonists show potential as a therapy for CIDP, they must prove their safety and efficacy in comparison to immunoglobulins to gain CIDP market share and patient acceptance. The cost of these novel molecules is also a major concern in the upcoming CIDP market.

Moreover, CIDP treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the CIDP market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the CIDP market growth.

Scope of the Chronic Inflammatory Demyelinating Polyneuropathy Market Report

• Therapeutic Assessment: Chronic Inflammatory Demyelinating Polyneuropathy current marketed and emerging therapies
• Chronic Inflammatory Demyelinating Polyneuropathy Market Dynamics: Key Market Forecast Assumptions of Emerging Chronic Inflammatory Demyelinating Polyneuropathy Drugs and Market Outlook
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Chronic Inflammatory Demyelinating Polyneuropathy Market Access and Reimbursement

Discover more about CIDP drugs in development @ Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trials

Table of Contents

Related Reports

Chronic Inflammatory Demyelinating Polyneuropathy Pipeline

Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CIDP companies, including Takeda, Sanofi, Johnson & Johnson Services, Immunovant, UCB S.A., GeNeuro, Nanjing IASO Biotherapeutics, Bioasis Technologies, Inc., among others.

Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology Forecast

Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted CIDP epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Myasthenia Gravis Market

Myasthenia Gravis Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key myasthenia gravis companies including DAS-MG, Inc, Catalyst Pharmaceuticals, Inc., Cabaletta Bio, Janssen Research & Development, LLC, Argenx, UCB Pharma, Alexion, Immunovant Sciences GmbH, Cartesian Therapeutics, Ra Pharmaceuticals, Inc., among others.

Myasthenia Gravis Pipeline

Myasthenia Gravis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myasthenia gravis companies, including Viela Bio, UCB Pharma, Momenta Pharmaceuticals, Sanofi, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Hoffmann-La Roche, Alexion Pharmaceuticals, Catalyst Pharmaceuticals, Harbour BioMed, Novartis, Takeda, DAS Therapeutics, RemeGen, Cartesian Therapeutics, Nanjing IASO Biotherapeutics, Cabaletta Bio, CytoDyn, Ahead Therapeutics, Toleranzia, Rallybio,  among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur 

[email protected] 

+91-9650213330 

www.delveinsight.com

Logo - https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP

21%

more press release views with 

Request a Demo